{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:47:27Z","timestamp":1769640447095,"version":"3.49.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Premenopausal women with high-risk hormone receptor (HR)-positive breast cancer often receive ovarian function suppression (OFS) with aromatase inhibitor therapy; however, abrupt menopause induction, together with further decrements in estrogen exposure through aromatase inhibition, may affect cardiovascular microcirculatory function. We examined adenosine-induced changes in left ventricular (LV) myocardial T1, a potential subclinical marker of LV microcirculatory function in premenopausal women undergoing treatment for breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-one premenopausal women (14 with HR-positive breast cancer receiving OFS with an aromatase inhibitor and 7 comparator women with triple-negative breast cancer [TNBC] who had completed primary systemic therapy) underwent serial resting and adenosine cardiovascular magnetic resonance imaging measurements of LV myocardial T1 and LV volumes, mass, and ejection fraction. All statistical tests were 2-sided.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After a median of 4.0\u2009months (range\u2009=\u20093.1-5.7\u2009months), the stress to resting ratio of LV myocardial T1 declined in women with HR-positive breast cancer (\u22121.3%, 95% confidence interval [CI]\u2009=\u2009\u22123.4% to 0.7%) relative to those with TNBC (3.2%, 95% CI\u2009=\u2009\u22121.2% to 7.6%, P\u2009=\u2009.02). After accounting for age, LV stroke volume, LV ejection fraction, diastolic blood pressure, and breast cancer subtype women with HR-positive breast cancer experienced a blunted T1 response after adenosine relative to women with TNBC (difference\u2009=\u2009\u22124.7%, 95% CI = \u22127.3% to \u22122.1%, Pdifference\u2009=\u2009.002).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Over the brief interval examined, women with HR-positive breast cancer receiving OFS with an aromatase inhibitor experienced reductions in adenosine-associated changes in LV myocardial T1 relative to women who received nonhormonal therapy for TNBC. These findings suggest a possible adverse impact on LV myocardial microcirculatory function in premenopausal women with breast cancer receiving hormone deprivation therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkab071","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T03:06:27Z","timestamp":1627268787000},"source":"Crossref","is-referenced-by-count":6,"title":["Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1001-1849","authenticated-orcid":false,"given":"Jennifer H","family":"Jordan","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA, USA"},{"name":"Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University Health Sciences, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Ralph B","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, Wake Forest University Health Sciences, Winston-Salem, NC, USA"},{"name":"Wake Forest Comprehensive Cancer Center, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Ansley","sequence":"additional","affiliation":[{"name":"Wake Forest Comprehensive Cancer Center, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Douglas","sequence":"additional","affiliation":[{"name":"Wake Forest Comprehensive Cancer Center, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Melin","sequence":"additional","affiliation":[{"name":"Wake Forest Comprehensive Cancer Center, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Sorscher","sequence":"additional","affiliation":[{"name":"Wake Forest Comprehensive Cancer Center, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujethra","family":"Vasu","sequence":"additional","affiliation":[{"name":"Wake Forest Comprehensive Cancer Center, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Kotak","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5393-9984","authenticated-orcid":false,"given":"Paul A","family":"Romitti","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, IA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathanial S","family":"O\u2019Connell","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, Wake Forest University Health Sciences, Winston-Salem, NC, USA"},{"name":"Wake Forest Comprehensive Cancer Center, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G","family":"Hundley","sequence":"additional","affiliation":[{"name":"Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University Health Sciences, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9022-2229","authenticated-orcid":false,"given":"Alexandra","family":"Thomas","sequence":"additional","affiliation":[{"name":"Wake Forest Comprehensive Cancer Center, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"issue":"1","key":"2021083110405890000_pkab071-B1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-009-0388-z","article-title":"Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer","volume":"119","author":"Han","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2021083110405890000_pkab071-B2","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1200\/JCO.2010.28.9199","article-title":"Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?","volume":"29","author":"Anders","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021083110405890000_pkab071-B3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s13058-014-0427-5","article-title":"Biology of breast cancer in young women","volume":"16","author":"Azim","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2021083110405890000_pkab071-B4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdf039","article-title":"Very young women (&lt;35 years) with operable breast cancer: features of disease at presentation","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann Oncol"},{"issue":"6","key":"2021083110405890000_pkab071-B5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.breast.2013.08.006","article-title":"Pathological features and survival outcomes of very young patients with early breast cancer: how much is \u201cvery young.\u201d?","volume":"22","author":"Cancello","year":"2013","journal-title":"Breast"},{"issue":"6","key":"2021083110405890000_pkab071-B6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3322\/caac.21412","article-title":"Breast cancer statistics, 2017, racial disparity in mortality by state","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2021083110405890000_pkab071-B7","doi-asserted-by":"crossref","first-page":"pkz040","DOI":"10.1093\/jncics\/pkz040","article-title":"Incidence and survival among young women with stage I-III breast cancer: SEER 2000-2015","volume":"3","author":"Thomas","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"10","key":"2021083110405890000_pkab071-B8","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1158\/1055-9965.EPI-12-0474","article-title":"Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades","volume":"21","author":"Haque","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"2021083110405890000_pkab071-B9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2021083110405890000_pkab071-B10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2021083110405890000_pkab071-B11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"2021083110405890000_pkab071-B12","author":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer"},{"issue":"2","key":"2021083110405890000_pkab071-B13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000516114","article-title":"St. Gallen\/Vienna 2021: a brief summary of the consensus discussion on customizing therapies for women with early breast cancer","volume":"16","author":"Thomssen","year":"2021","journal-title":"Breast Care (Basel)"},{"issue":"5","key":"2021083110405890000_pkab071-B14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1056\/NEJMe1413164","article-title":"Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains","volume":"372","author":"Hershman","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2021083110405890000_pkab071-B15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jnci\/djx023","article-title":"Risk of heart disease in breast cancer patients receiving estrogen-deprivation therapy","volume":"109","author":"Sindzinski","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"2021083110405890000_pkab071-B16","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1505241","article-title":"Vascular effects of early versus late postmenopausal treatment with estradiol","volume":"374","author":"Hodis","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2021083110405890000_pkab071-B17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0735-1097(02)02763-8","article-title":"Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study","volume":"41","author":"Bairey Merz","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2021083110405890000_pkab071-B18","doi-asserted-by":"crossref","first-page":"j372","DOI":"10.1136\/bmj.j372","article-title":"Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage","volume":"356","author":"Mytton","year":"2017","journal-title":"BMJ"},{"issue":"11","key":"2021083110405890000_pkab071-B19","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.mayocp.2016.08.002","article-title":"Accelerated accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study","volume":"91","author":"Rocca","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2021083110405890000_pkab071-B20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","article-title":"Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses' Health Study","volume":"121","author":"Parker","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2021083110405890000_pkab071-B21","volume-title":"StatPearls","author":"Peters","year":"2021"},{"key":"2021083110405890000_pkab071-B22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0093-7754(03)00302-6","article-title":"Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer","volume":"30","author":"Miller","year":"2003","journal-title":"Semin Oncol"},{"key":"2021083110405890000_pkab071-B23","doi-asserted-by":"crossref","first-page":"k3845","DOI":"10.1136\/bmj.k3845","article-title":"Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review","volume":"363","author":"Matthews","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"2021083110405890000_pkab071-B24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Arimidex","year":"2008","journal-title":"Lancet Oncol"},{"issue":"9484","key":"2021083110405890000_pkab071-B25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"issue":"9561","key":"2021083110405890000_pkab071-B26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"issue":"10001","key":"2021083110405890000_pkab071-B27","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2015","journal-title":"Lancet"},{"key":"2021083110405890000_pkab071-B28","author":"NCT03505736"},{"issue":"1","key":"2021083110405890000_pkab071-B29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12968-020-00607-1","article-title":"Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update","volume":"22","author":"Kramer","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"2021083110405890000_pkab071-B30","doi-asserted-by":"crossref","first-page":"e011774","DOI":"10.1161\/CIRCIMAGING.120.011774","article-title":"Molecular mechanisms of adenosine stress T1 mapping","volume":"14","author":"Shah","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"2021083110405890000_pkab071-B31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10334-017-0649-5","article-title":"State-of-the-art review: stress T1 mapping-technical considerations, pitfalls and emerging clinical applications","volume":"31","author":"Piechnik","year":"2018","journal-title":"Magma"},{"issue":"25","key":"2021083110405890000_pkab071-B32","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2021083110405890000_pkab071-B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12968-018-0484-5","article-title":"Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I-analytical validation and clinical qualification","volume":"20","author":"Puntmann","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"2021083110405890000_pkab071-B34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcmg.2015.08.018","article-title":"Adenosine stress and rest T1 mapping can differentiate between ischemic, infarcted, remote, and normal myocardium without the need for gadolinium contrast agents","volume":"9","author":"Liu","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"2021083110405890000_pkab071-B35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/jnci\/djx135","article-title":"Racial differences in PAM50 subtypes in the Carolina Breast Cancer Study","volume":"110","author":"Troester","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2021083110405890000_pkab071-B36","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0360-3016(02)04156-1","article-title":"Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution","volume":"55","author":"Lind","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2021083110405890000_pkab071-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-6-151","article-title":"Myocardial perfusion imaging with 99 m Tc-tetrofosmin SPECT in breast cancer patients that received postoperative radiotherapy: a case-control study","volume":"6","author":"Sioka","year":"2011","journal-title":"Radiat Oncol"},{"issue":"10","key":"2021083110405890000_pkab071-B38","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jcmg.2018.12.022","article-title":"Automated pixel-wise quantitative myocardial perfusion mapping by CMR to detect obstructive coronary artery disease and coronary microvascular dysfunction: validation against invasive coronary physiology","volume":"12","author":"Kotecha","year":"2019","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkab071\/39350625\/pkab071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jncics\/article-pdf\/5\/4\/pkab071\/40136942\/pkab071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jncics\/article-pdf\/5\/4\/pkab071\/40136942\/pkab071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:41:37Z","timestamp":1630406497000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkab071\/6329268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkab071","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,7,6]]},"article-number":"pkab071"}}